<DOC>
	<DOCNO>NCT02617238</DOCNO>
	<brief_summary>Randomised two parallel group multicenter study use Prospective Randomised Open Blinded End-point design ( PROBE ) , aim compare efficacy therapeutic strategy target normalisation arterial stiffness reduce cardiovascular ( CV ) renal event , comparison classical therapeutic strategy implement European Society Hypertension-European Society Cardiology ( ESH-ESC ) Guidelines , patient essential hypertension medium-to-very high CV risk .</brief_summary>
	<brief_title>Strategy Preventing Cardiovascular Renal Events Based ARTErial Stiffness</brief_title>
	<detailed_description>The objective show therapeutic strategy target implementation international guideline PLUS normalisation blood pression ( BP &lt; 140 90 mmHg ) plus normalisation arterial stiffness ( measure every 6 month ) Pulse Wave Velocity group ( PWV group ) reduce CV renal event significantly great extent sole implementation Guidelines ( conventional group , PWV measurement baseline every 2 year ) . Experimental design : Prospective Randomised Open Blinded Endpoint ( PROBE ) multicenter , two parallel group , study . Therapeutic strategy PWV group : 1 . Use maximal recommended dos angiotensin-converting-enzyme inhibitor ( ACEIs ) Angiotensin II receptor blocker ( ARBs ) first step treatment . And adapt treatment PWV value . 2 . In second step , use combination therapy Calcium channel blocker ( CCBs ) 3 . Use diuretic combination therapy , either alternative CCBs second step triple therapy third step 4 . Use , fourth step , vasodilating beta-blockers ( VD-BB ) spironolactone 5 . In parallel , correct CV risk factor accord ESH-ESC Guidelines , reinforce treatment ( hypolipidemic drug , glucose lower drug , antiplatelets ) secondary prevention . Therapeutic strategy conventional group : Apply ESH-ESC Guidelines</detailed_description>
	<criteria>registration French social security system patient specifically express non willingness participate PLUS either A , B C : 1 . Patients essential hypertension , age 55 75 year old , sexes Grade 1 hypertension Treated Whatever control BP Under primary secondary prevention ( 3 month stroke myocard infarctus ( MI ) , stable angina peripheral artery disease ) PLUS least 3 CV risk factor accord ESHESC 2007 guideline metabolic syndrome associate least 2 follow criterion SBP/DBP 130/85 mmHg HDLC &lt; 1.0 mmol/l ( 0,4 g/l ) ( M ) &lt; 1.2 mmol/l ( 0,46 g/l ) ( F ) Triglycerides &gt; 1,7 mmol/l ( &gt; 1,5 g/l ) Fasting blood glucose 5,6 6,9 mmol/l ( 1,021,25 g/l ) Waist circumference &gt; 102 cm ( M ) ou 88 cm ( F ) Type 2 diabetes Target organ damage , accord definition ESHESC Guidelines Management Hypertension CV disease chronic kidney disease 2 . SBP &gt; 180 mmHg and/or DBP &gt; 110 mmHg 3 . SBP &gt; 160 mmHg AND DBP &lt; 70 mmHg Patients ABPM selfmeasurement normal without treatment ( &lt; 130 mmHg 80 ABPM 24 &lt; 135 85 mmHg daytime ABPM selfmeasurement blood pressure ) Patients secondary hypertension ( renal artery stenosis , pheochromocytoma , hypermineralocortisism ) Patients hypertension secondary diabetic nephropathy Patients age 55 75 year , Lowrisk CV patient Patients severe chronic renal impairment creatinine clearance ( MDRD ) &lt; 30ml / min / 1.73m2 Patients type I diabetes Patients severe disease threaten vital prognosis short medium term Patients previously experience painful gynecomastia spironolactone Patients alcohol dependence excessive consumption alcoholic beverage ( judgement investigator ) patient accident history neurovascular , coronary insufficiency ( coronary bypass surgery percutaneous coronary intervention ) old 3 month Patients history acute heart failure open failure heart ( NYHA class IIIIV ) Patients unstable angina Auricular Fibrillation ( AF ) less 6 month ago Patients aortic stent Patients know aneurysms abdominal aorta Patients atrioventricular block second third degree without pacemaker Patients receive organ transplant place wait list transplantation Patients severe chronic inflammatory disease ( rheumatoid arthritis ; lupus ; scleroderma ... ) Patients severe chronic infectious disease Patients MI le 3 month ago Patients stroke less 3 month ago Patients progression peripheral arterial disease Patient whose pregnancy know effective contraception childbearing age , breastfeed Patients express opposition participate protocol inability understand follow protocol The patient geographically far place investigation Patients already participate drug research protocol Interventional</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>arterial stiffness</keyword>
	<keyword>cardiovascular risk</keyword>
	<keyword>cardiovascular event</keyword>
	<keyword>renal event</keyword>
</DOC>